Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Rhea-AI Summary

Armata Pharmaceuticals (NYSE American: ARMP), a biotechnology company specializing in bacteriophage therapeutics for antibiotic-resistant infections, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is set to take place in New York from September 9-11, 2024.

Dr. Deborah Birx, Armata's Chief Executive Officer, will deliver a corporate presentation on Wednesday, September 11, from 8:00-8:30 AM ET. This presentation offers an opportunity for investors to gain insights into Armata's innovative approach to treating difficult-to-treat bacterial infections using high-purity, pathogen-specific bacteriophage therapeutics.

News Market Reaction

-3.03%

1 alert

-3.03% News Effect

On the day this news was published, ARMP declined 3.03%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

LOS ANGELES, Sept. 5, 2024 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D., Chief Executive Officer, will participate in a corporate presentation at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held in New York from September 9-11, 2024.

Armata's presentation is scheduled for Wednesday, September 11, from 8:00-8:30 AM ET.

About Armata Pharmaceuticals, Inc.

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.

Media Contacts:

At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
ir@armatapharma.com
310-665-2928 x234

Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569

View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-to-participate-in-the-hc-wainwright-26th-annual-global-investment-conference-302238686.html

SOURCE Armata Pharmaceuticals, Inc.

FAQ

When is Armata Pharmaceuticals (ARMP) presenting at the H.C. Wainwright Global Investment Conference?

Armata Pharmaceuticals (ARMP) is scheduled to present on Wednesday, September 11, 2024, from 8:00-8:30 AM ET at the H.C. Wainwright 26th Annual Global Investment Conference in New York.

Who will be presenting for Armata Pharmaceuticals (ARMP) at the H.C. Wainwright conference?

Dr. Deborah Birx, the Chief Executive Officer of Armata Pharmaceuticals, will deliver the corporate presentation at the H.C. Wainwright conference.

What is the focus of Armata Pharmaceuticals' (ARMP) research?

Armata Pharmaceuticals (ARMP) focuses on developing high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections.

Where is the H.C. Wainwright Global Investment Conference being held in 2024?

The H.C. Wainwright 26th Annual Global Investment Conference is being held in New York from September 9-11, 2024.